A multicenter, prospective, randomized, 2-way crossover, open-label study in postmenopausal women with osteoporosis examining subject satisfaction and compliance when risedronate sodium [risedronic acid](Actonel) is administered 35mg once a week or 5mg once daily.
Phase of Trial: Phase IV
Latest Information Update: 07 Jul 2009
At a glance
- Drugs Risedronic acid (Primary)
- Indications Postmenopausal osteoporosis
- Focus Therapeutic Use
- Sponsors Sanofi
- 31 Aug 2018 Biomarkers information updated
- 07 Jun 2007 New trial record.